Table 1 Summary of baseline characteristics and demographic data (ITT population)
BF Spiromax (n = 303) | BF Turbuhaler (n = 302) | |
|---|---|---|
Age, years (mean ± SD) | 48.1 ± 16.24 | 46.9 ± 16.89 |
Sex, n (%) | ||
Male | 131 (43) | 141 (47) |
Female | 172 (57) | 161 (53) |
Race, n (%) | ||
White | 297 (98) | 300 (>99) |
Black | 2 (<1) | 1 (<1) |
Asian | 1 (<1) | 1 (<1) |
Other | 3 (<1) | 0 (0) |
Weight, Kg (mean ± SD) | 77.4 ± 17.25 | 78.6 ± 17.88 |
Median weekly averaged AM PEF, L/min (range) | 318.6 (82.9–632.9) | 345.7 (108.6–604.3) |
Median weekly averaged PM PEF, L/min (range) (L/min) | 328.6 (98.6–650.0) | 352.9 (127.1–635.7) |
Median baseline FEV1, L (range) (L) | 2.1 (0.9–4.2) | 2.3 (0.8–4.0) |
Prior asthma medications, ≥5 % (n [%]) | ||
Salbutamol | 290 (96) | 281 (93) |
Budesonide | 145 (48) | 139 (46) |
Fluticasone | 77 (25) | 73 (24) |
Budesonide–formoterol | 48 (16) | 43 (14) |
Fluticasone and salmeterol | 43 (14) | 37 (12) |
Average symptom-free 24-hour period, % (mean ± SD) | 19 ± 31.67a | 15.3 ± 26.4b |
Average rescue-free 24-hour period, % (mean ± SD) | 33.3 ± 38.26a | 30.9 ± 37.02b |